VK-2019
VK-2019 is an oral active, selective EBNA1 ((Epstein-Barr Nuclear Antigen 1) inhibitor and can be used for study of EBV-associated carcinomas[1].
Product Specifications
CAS Number
[2044520-06-9]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
EBV
Type
Reference compound
Related Pathways
Anti-infection
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vk-2019.html
Purity
99.97
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=C(C2=CC3=C(C=CN3)C=C2)C(C#CC4=CC=C(COC5CCOCC5)C=C4)=CC=C1)O
Molecular Formula
C29H25NO4
Molecular Weight
451.51
Precautions
H302, H315, H319, H335
References & Citations
[1]Davis MT, et al. Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK-2019, a selective EBNA1 inhibitor. Biomed Chromatogr. 2024;38 (2) :e5775.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
132648-AP 100 µL
RING Finger Protein 133 (RNF133, E3 Ubiquitin-protein Ligase RNF133) (AP) discontinued
Ask
View Details bs-5563R-BF647 100 µL
Phospho-PRKD1 (Tyr463) Polyclonal Antibody, AbBy Fluor™ 647 Conjugated
Ask
View Details MBS1041891-01 0.02 mg (E-Coli)
Recombinant Saccharomyces cerevisiae DNA-directed RNA polymerases I and III subunit RPAC2 (RPC19)
Ask
View Details 
MBS1041891-02 0.1 mg (E-Coli)
Recombinant Saccharomyces cerevisiae DNA-directed RNA polymerases I and III subunit RPAC2 (RPC19)
Ask
View Details